TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 69.0%

Neg 69% Neu 0% Pos 0%

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.